Efficacy of Transcutaneous Electrical Acupoint Stimulation as a Preventive Measure Against Lymphedema in Breast Cancer Patients Undergoing Axillary Lymph Node Dissection: A Protocol for a Randomized Controlled Trial - Takeaways - MDSpire

Efficacy of Transcutaneous Electrical Acupoint Stimulation as a Preventive Measure Against Lymphedema in Breast Cancer Patients Undergoing Axillary Lymph Node Dissection: A Protocol for a Randomized Controlled Trial

  • By

  • Linna Wu

  • Qing Mao

  • Zhu Zhu

  • Jun Yang

  • Liang Chen

  • Xingtai Hu

  • Qilian Xia

  • Yongliang Wang

  • Shiyi Tang

  • Yu Zhou

  • Aimei Jiang

  • Rong Zhao

  • April 29, 2026

  • 0 min

Share

  • 1

    Transcutaneous electrical acupoint stimulation (TEAS) may serve as a preventive measure against breast cancer-related lymphedema (BCRL).

  • 2

    The study will involve 72 breast cancer patients undergoing axillary lymph node dissection, randomized into TEAS and Sham TEAS groups.

  • 3

    Primary outcomes include the incidence and onset timing of lymphedema within 18 months post-surgery.

  • 4

    Secondary outcomes will assess perceived swelling, limb circumference, and serum inflammatory factors at multiple time points.

  • 5

    If effective, TEAS could provide a non-invasive adjunct therapy for preventing lymphedema in breast cancer patients.

Original Source(s)

Efficacy of Transcutaneous Electrical Acupoint Stimulation as a Preventive Measure Against Lymphedema in Breast Cancer Patients Undergoing Axillary Lymph Node Dissection: A Protocol for a Randomized Controlled Trial

  • by Linna Wu, Qing Mao, Zhu Zhu, Jun Yang, Liang Chen, Xingtai Hu, Qilian Xia, Yongliang Wang, Shiyi Tang, Yu Zhou, Aimei Jiang, Rong Zhao

  • April 29, 2026

Related Content

Clinician Perspectives on Implementing Breast Cancer–Related Lymphedema Prospective Screening

HiGATE: hierarchical graph attention for multi-scale tissue encoder in computational pathology

Case Report: A case of a pregnancy-associated breast cancer patient with a pathogenic variant in BRCA1 who underwent staged risk-reducing salpingo-oophorectomy and contralateral risk-reducing mastectomy